ホーム>>Signaling Pathways>> DNA Damage/DNA Repair>> Checkpoint Kinase (Chk)>>GDC-0575 (ARRY-575, RG7741)

GDC-0575 (ARRY-575, RG7741)

カタログ番号GC32885

GDC-0575 (ARRY-575, RG7741) (ARRY-575, RG7741) は、IC50 が 1.2nM の選択性の高い経口低分子 Chk1 阻害剤です。

Products are for research use only. Not for human use. We do not sell to patients.

GDC-0575 (ARRY-575, RG7741) 化学構造

Cas No.: 1196541-47-5

サイズ 価格 在庫数 個数
10mM (in 1mL DMSO)
$177.00
在庫あり
5mg
$161.00
在庫あり
10mg
$246.00
在庫あり
25mg
$468.00
在庫あり
50mg
$702.00
在庫あり
100mg
$1,053.00
在庫あり

Tel:(909) 407-4943 Email: sales@glpbio.com


顧客レビュー

カスタマーレビューに基づきます。

  • GlpBio Citations

    GlpBio Citations
  • Bioactive Compounds Premium Provider

    Bioactive Compounds Premium Provider

Sample solution is provided at 25 µL, 10mM.

Description Protocol Chemical Properties Product Documents Related Products

GDC-0575 (ARRY-575, RG7741) is a highly-selective oral small-molecule Chk1 inhibitor with an IC50 of 1.2 nM.

GDC-0575 is significantly more potent in promoting DNA damage, replication stress and cell death than V158411, LY2603618, and MK-8776 in a panel of melanoma cell lines[1]. GDC-0575 abrogates DNA damage-induced S and G2-M checkpoints, exacerbates DNA double-strand breaks and induces apoptosis in STS cells. GDC-0575 has a synergistic or additive effect together with gemcitabine[2]. CHK1 inhibitor GDC-0575 in combination with AraC enhances the killing of primary acute myeloid leukemia cells ex vivo by inducing apoptosis[3].

GDC-0575 is active at 25 mg/kg as a single agent, but the efficacy is improved at the higher drug dose. GDC-0575 effectively blocks tumor growth in the D20 and C002 xenografts, and the effect is maintained for at least 10 days after the final dose is administered[1].

[1]. Oo ZY, et al. Endogenous Replication Stress Marks Melanomas Sensitive to CHEK1 Inhibitors In Vivo. Clin Cancer Res. 2018 Mar 13. doi: 10.1158/1078-0432.CCR-17-2701. [2]. Laroche-Clary A, et al. CHK1 inhibition in soft-tissue sarcomas: biological and clinical implications. Ann Oncol. 2018 Apr 1;29(4):1023-1029. [3]. Di Tullio A, et al. The combination of CHK1 inhibitor with G-CSF overrides cytarabine resistance in human acute myeloid leukemia. Nat Commun. 2017 Nov 22;8(1):1679.

レビュー

Review for GDC-0575 (ARRY-575, RG7741)

Average Rating: 5 ★★★★★ (Based on Reviews and 9 reference(s) in Google Scholar.)

5 Star
100%
4 Star
0%
3 Star
0%
2 Star
0%
1 Star
0%
Review for GDC-0575 (ARRY-575, RG7741)

GLPBIO products are for RESEARCH USE ONLY. Please make sure your review or question is research based.

Required fields are marked with *

You may receive emails regarding this submission. Any emails will include the ability to opt-out of future communications.